Cabinet approves replacement for 56-year-old nuclear reactor at Pelindaba

Written by Ciaran Ryan. Posted in Journalism

It comes at a cost of about R12bn and should be operational by 2032. From Moneyweb.

The Pelindaba nuclear research centre near Hartbeespoort Dam in North West Province. Image: Necsa website
The Pelindaba nuclear research centre near Hartbeespoort Dam in North West Province. Image: Necsa website

Cabinet has approved a replacement for the 56-year-old Safari-1 nuclear reactor at Pelindaba, which catapulted South Africa to world leadership in the production of medical isotopes used in the treatment of cancer.

The Safari-1 reactor is operated by the South African Nuclear Energy Corporation (Necsa) at Pelindaba, west of Pretoria. It will be replaced by a multipurpose reactor (MPR) which is expected to cost about R12 billion, with construction expected to start in 2026 and be completed in 2032.

“There will be some 5 000 direct and 26 000 indirect jobs created during construction,” says Necsa chair David Nicholls.

“The nuclear reactor will provide employment to about 750 full-time employees and an additional 3 800 indirect jobs for its operation and fulfilment of its research mandate at the NBLC [Neutron Beam Line Centre] during its operational lifetime.”

The MPR project moved into the feasibility phase in April 2021, a process that will last until about March 2023. Part of this process includes a request for information (RFI) from potential vendors, which will also indicate potential cost. The RFI is expected to go out to the market next month.

Flexibility and efficiency

The new reactor will have a life of about 60 years and will have far greater flexibility and efficiencies than the current reactor.

Necsa CEO Loyiso Tyabashe says the new reactor will ensure SA remains among the top four producers of radioisotopes in the world and is able to continue its cutting edge research and development in this field.

The MPR provides a wider range of manufacturing possibilities and potential markets that can be harnessed, and will allow Necsa to produce new radioisotopes that are seen as the future in therapeutic nuclear medicine.

This includes the production of short-range radioisotopes that will be delivered by smart delivery systems to tumour cells, radiating cell by cell and thereby eliminating the cancer while preserving surrounding healthy tissue.

Relationship with regulator has ‘stabilised’

As Moneyweb previously reported, the National Nuclear Regulator (NNR) shut down the Safari-1 reactor on several occasions over violations of safety protocols, which were administrative rather than physical breaches of safety.

Read:SA’s nuclear medical plant shut down – again

Suspended nuclear company execs smell rat over adverse audit

Axed Necsa board blames resistance of ‘privatisation by stealth’ for dismissal

These shutdowns resulted in Necsa losing market share to competitors. Nicholls says the situation with the regulator has stabilised over the last year, allowing Necsa to regain lost market share.

Necsa currently has about 20% of the world market for medical isotopes.

Due to the short half-life of these medicines, products have to be shipped to patients within a day of manufacture to have the desired therapeutic effect. The reactor shutdown by the regulator forced customers to approach competitors capable of meeting the strict supply timelines for therapeutic treatment.

Leading role in world market

The reactor is widely used by researchers and academia in SA and across the continent, giving SA a seat at the nuclear table internationally. In a statement, Necsa says the MPR will expand these research capabilities and outputs substantially in that it will be equipped with a cold neutron source that extends the delivered range of neutrons to long wavelengths (very low energies).

“The inclusion of a cold neutron source in the MPR will also make it the only cold-neutron source available in Africa, and thus may attract interest from the region and continent,” says Necsa.

“This capability will be located at the Neutron Beam Line Centre (NBLC) that will be associated with the MPR and will act as a new large-scale research hub, equipped with an extensive suite of neutron-scattering applications.”

The new reactor will benefit the domestic and international healthcare sector, particularly in the treatment of cancer, through Necsa’s leadership in the research and production of therapeutic radiopharmaceuticals.

Other sectors that will benefit from the MPR are mining and industry, power generation, agriculture, geosciences, forensics and education.

“The MPR project is expected to have significant social, economic and environmental benefits for the country. A substantial portion of products will be sourced locally during the MPR construction, [and] thus boost the local and national economy,” says Nicholls.

Read: SA’s nuclear energy housekeeping costs – who will foot the bill?

Ciaran Ryan

The Writer's Room is a curated by Ciaran Ryan, who has written on South African affairs for Sunday Times, Mail & Guardian, Financial Mail, Finweek, Noseweek, The Daily Telegraph, Forbes, USA Today, Acts Online and, among others. In between he manages a gold mining operation in Ghana, and previously worked in Congo. Most of his time is spent in the lovely city of Joburg.